top of page

Piotr Witkowski


 since 2009

Islet Cell 
Kidney Transplantation
Immune Regulatory T Cell Therapy




As a transplant surgeon, I help patients who require kidney and/or pancreas transplantation.

As a scientist, I am mainly focused on translational

research testing and bringing novel technologies 

and procedures to clinical practice. 


For the past 9 years, I have been optimizing pancreatic islet transplantation as  a minimally invasive procedure to achieve improved blood glucose control and freedom from insulin in our patients.

Another objective I have is to minimize, and eventually eliminate, the need for toxic anti-rejection medications for transplant protection (to induce immunologic tolerance- the Holy Grail of transplantation).


To meet this goal, I am preparing a novel cellular therapy based on ex-vivo expanded  T regulatory cells (Tregs). We have already optimized  Treg production in our clinical Laboratory. This therapy can not only benefit transplant patients, but also those with autoimmune disorders like type 1 diabetes, Crohn's disease, multiple sclerosis or rheumatoid arthritis.


Currently, we are also conducting several different clinical trials testing novel 

approaches to improve outcomes in kidney and pancreatic islet transplantation.

For more details, see links above for Diabetes, Pancreatitis and Kidney Tx.


Thank you for your interest in our research. 

Piotr Witkowski M.D. Ph.D.

Associate Professor of Surgery

Director, Pancreatic Islet Transplantation Program

Director, Transplant Surgery Fellowship Program

Director, Polish- American Transplant Center


Transplantation Institute

University of Chicago Medicine

bottom of page